GSK, Vir barrel into a fast PhII/III for their lead Covid-19 antibody, chasing a moving target with quick OK in sight
Now that Eli Lilly and Regeneron have strayed off schedule on the development of new antibodies to fight Covid-19, GlaxoSmithKline execs and their partners at Vir are jumping into the clinic. And they say they could have the first data cut ahead of the end of this year, with late-stage data in Q1 coming up that could put them on a short path to a quick OK at the FDA.
The move comes as all the companies involved in antibody R&D wonder just how big their market could be as new and uncertain vaccines shape the market in 2021. That’s a moving target, with major implications for everyone involved. And some of the analysts covering the race are skeptical that GSK and Vir can play a leading role now that they let others jump clearly out front.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.